Tyra Biosciences (TYRA) Depreciation & Amortization (CF) (2020 - 2026)
Tyra Biosciences' (TYRA) quarterly Depreciation & Amortization (CF) came in at $138000.0 in Q1 2026, down 3.5% YoY from $143000.0 in Q1 2025, and up 4.55% on a QoQ basis from $132000.0 in Q4 2025.
Powered by 
Analysis
Tyra Biosciences (TYRA) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Tyra Biosciences (TYRA) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $138000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 3.5% year-over-year to $138000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $541000.0 (changed 0.19% YoY) and the FY2025 annual result came in at $546000.0, up 5.2% from the prior year.
- Depreciation & Amortization (CF) improved to $138000.0 in Q1 2026, from $132000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $144000.0 in Q4 2024 to a low of $64000.0 in Q1 2022.
- A 5-year average of $109176.5 and a median of $122000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) surged 190.91% — and 2025, when it declined 8.33%.
- Tracing TYRA's Depreciation & Amortization (CF) over 5 years: stood at $82000.0 in 2022, then grew by 24.39% to $102000.0 in 2023, then soared by 41.18% to $144000.0 in 2024, then fell by 8.33% to $132000.0 in 2025, then increased by 4.55% to $138000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $138000.0 (Q1 2026), $132000.0 (Q4 2025), and $131000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Tyra Biosciences | 1.94 Bn | 1.94 Bn | - | 138,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 138,000.00 |
| Mar 31, 2026 | 138,000.00 |
| Dec 31, 2025 | 132,000.00 |
| Sep 30, 2025 | 131,000.00 |
| Jun 30, 2025 | 140,000.00 |
| Mar 31, 2025 | 143,000.00 |
| Dec 31, 2024 | 144,000.00 |
| Sep 30, 2024 | 127,000.00 |
| Jun 30, 2024 | 126,000.00 |
| Mar 31, 2024 | 122,000.00 |
| Dec 31, 2023 | 102,000.00 |
| Sep 30, 2023 | 83,000.00 |
| Jun 30, 2023 | 89,000.00 |
| Mar 31, 2023 | 83,000.00 |
| Dec 31, 2022 | 82,000.00 |
| Sep 30, 2022 | 82,000.00 |
| Jun 30, 2022 | 68,000.00 |
| Mar 31, 2022 | 64,000.00 |
| Dec 31, 2021 | 50,000.00 |
| Sep 30, 2021 | 41,000.00 |